<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of 2-oindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards" exact="colorectal cancer" post="cells W. M. Eldehna et al. EldehnaWagdy M.aAbo-AshourMahmoud F.bAl-WarhiTarfahcAl-RashoodSara"/>
 <result pre="2-oindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards colorectal" exact="cancer" post="cells W. M. Eldehna et al. EldehnaWagdy M.aAbo-AshourMahmoud F.bAl-WarhiTarfahcAl-RashoodSara"/>
 <result pre="Bcl2 and BclxL inhibitors. The progression of the two examined" exact="colorectal cancer" post="cell lines was significantly inhibited by all of the"/>
 <result pre="and BclxL inhibitors. The progression of the two examined colorectal" exact="cancer" post="cell lines was significantly inhibited by all of the"/>
 <result pre="further optimisation to develop novel pro-apoptotic and antitumor agents towards" exact="colon cancer." post="Keywords Anti-proliferative indoles apoptosis isatin-indole Bcl2/BclxL inhibitors colorectal cancer"/>
 <result pre="towards colon cancer. Keywords Anti-proliferative indoles apoptosis isatin-indole Bcl2/BclxL inhibitors" exact="colorectal cancer" post="western blotting fig-count: table-count: page-count: word-count: 1. Introduction Cancer"/>
 <result pre="colon cancer. Keywords Anti-proliferative indoles apoptosis isatin-indole Bcl2/BclxL inhibitors colorectal" exact="cancer" post="western blotting fig-count: table-count: page-count: word-count: 1. Introduction Cancer"/>
 <result pre="invade or spread to other body parts1. Since several decades," exact="cancer" post="has been one of the main world health problems"/>
 <result pre="a serious leading cause of death worldwide. Early strategies of" exact="cancer" post="treatment were based on the unspecific induction of cell"/>
 <result pre="effective and safe new antitumour drugs with increased selectivity towards" exact="cancer" post="cells is still an active search10,11. On the other"/>
 <result pre="targeted therapies target specific biomarkers essential for the regulation of" exact="cancer" post="cells proliferation and/or cell apoptosis such as deregulated, mutated,"/>
 <result pre="as deregulated, mutated, or overexpressed proteins12 and thus, selectively affect" exact="cancer" post="cells or their supporting environment with minimum effects on"/>
 <result pre="apoptosis14. In this regard, it was reported that most of" exact="cancer" post="cells are characterised by over-expression of the anti-apoptotic Bcl2"/>
 <result pre="different kinases34â€&quot;35, in addition to apoptosis induction in different human" exact="cancer" post="cell lines36â€&quot;37. Figure 1. Chemical structures for some reported"/>
 <result pre="antiproliferative effect of the new compounds against HT-29 and SW-620" exact="colorectal cancer" post="cell lines were examined. In addition, the levels of"/>
 <result pre="effect of the new compounds against HT-29 and SW-620 colorectal" exact="cancer" post="cell lines were examined. In addition, the levels of"/>
 <result pre="mitochondria-related anti-apoptotic proteins Bcl2 and BclxL in HT-29 and SW-620" exact="colorectal cancer" post="cell lines after incubation with isatin derivatives 7c and"/>
 <result pre="anti-apoptotic proteins Bcl2 and BclxL in HT-29 and SW-620 colorectal" exact="cancer" post="cell lines after incubation with isatin derivatives 7c and"/>
 <result pre="2.2. Biological evaluation 2.2.1. Anti-proliferative activity against HT-29 and SW-620" exact="colorectal cancer" post="cell lines The anti-proliferative potential of the final compounds"/>
 <result pre="Biological evaluation 2.2.1. Anti-proliferative activity against HT-29 and SW-620 colorectal" exact="cancer" post="cell lines The anti-proliferative potential of the final compounds"/>
 <result pre="final compounds (7a-j and 9a-e) was examined against two human" exact="colorectal cancer" post="HT-29 and SW-620 cell lines. While, HT-29 is an"/>
 <result pre="compounds (7a-j and 9a-e) was examined against two human colorectal" exact="cancer" post="HT-29 and SW-620 cell lines. While, HT-29 is an"/>
 <result pre="While, HT-29 is an adenocarcinoma cell line, SW-620 represents metastatic" exact="cancer" post="cell line. These effects were compared with known anti-cancer"/>
 <result pre="compared with known anti-cancer drug, 5-Fluorouracil (5FU) commonly used in" exact="colorectal cancer" post="treatment. All of the compounds were found to inhibit"/>
 <result pre="with known anti-cancer drug, 5-Fluorouracil (5FU) commonly used in colorectal" exact="cancer" post="treatment. All of the compounds were found to inhibit"/>
 <result pre="the compounds were found to inhibit the cell viability of" exact="cancer" post="cells with varied sub-micro-molar efficacy. The IC50 values ranged"/>
 <result pre="actions of compounds 7a-j and 9a-e towards HT-29 and SW-620" exact="colorectal cancer" post="cell lines. Comp. R R1 R2 IC50 (nM)a HT-29"/>
 <result pre="of compounds 7a-j and 9a-e towards HT-29 and SW-620 colorectal" exact="cancer" post="cell lines. Comp. R R1 R2 IC50 (nM)a HT-29"/>
 <result pre="indicates that compounds 7c and 7g inhibited cell viability of" exact="cancer" post="cells without affecting normal fibroblast. Figure 3. Effect of"/>
 <result pre="their potential role of apoptosis induction in the colorectal SW-620" exact="cancer" post="cell line (SW-620 cell line was selected because most"/>
 <result pre="proteins, are known to be overexpressed in diverse tumours causing" exact="cancer" post="cell survival and drug resistance14. Inhibition of these proteins"/>
 <result pre="and drug resistance14. Inhibition of these proteins expression resulted in" exact="cancer" post="cell death and has been exploited as a strategy"/>
 <result pre="5. (A) Effect of compound 7c on anti-apoptotic proteins. SW-620" exact="cancer" post="cells were treated with two concentrations of compound 7c"/>
 <result pre="p valuesâ€‰. *** pâ€‰ pâ€‰ 7g on anti-apoptotic proteins. SW-620" exact="cancer" post="cells were treated with two concentrations of compound 7g"/>
 <result pre="9a-e) was designed and synthesised as potential antiproliferative agents towards" exact="colon cancer" post="cells with promising inhibitory activity against the anti-apoptotic Bcl2"/>
 <result pre="was designed and synthesised as potential antiproliferative agents towards colon" exact="cancer" post="cells with promising inhibitory activity against the anti-apoptotic Bcl2"/>
 <result pre="Bcl2 and BclxL proteins. The cell growth of two examined" exact="colorectal cancer" post="(HT-29 and SW-620) cell lines was significantly inhibited by"/>
 <result pre="and BclxL proteins. The cell growth of two examined colorectal" exact="cancer" post="(HT-29 and SW-620) cell lines was significantly inhibited by"/>
 <result pre="were examined and proved to exhibit selective cytotoxicity against both" exact="cancer" post="cell lines with high safety profile to normal fibroblast"/>
 <result pre="13.16. 4.2. Biological evaluation 4.2.1. Cell culture HT29 and SW620" exact="colorectal cancer" post="cell lines and HFF-1 fibroblast (ATCC, Rockville, USA) were"/>
 <result pre="4.2. Biological evaluation 4.2.1. Cell culture HT29 and SW620 colorectal" exact="cancer" post="cell lines and HFF-1 fibroblast (ATCC, Rockville, USA) were"/>
 <result pre="Cell viability assay The cytotoxicity effect of compounds on the" exact="colorectal cancer" post="cell lines, HT29 and SW620 in addition to the"/>
 <result pre="viability assay The cytotoxicity effect of compounds on the colorectal" exact="cancer" post="cell lines, HT29 and SW620 in addition to the"/>
 <result pre="statistics 2016. CA. Cancer J Clin2016;66:7â€&quot;30. 2FarberS, DiamondLK.Temporary remissions in" exact="acute leukemia" post="in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid."/>
 <result pre="2016. CA. Cancer J Clin2016;66:7â€&quot;30. 2FarberS, DiamondLK.Temporary remissions in acute" exact="leukemia" post="in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid."/>
 <result pre="J Med1948;238:787â€&quot;93.18860765 3WadlerS, FuksJZ, WiernikPH.Phase I and II agents in" exact="cancer" post="therapy: I. Anthracyclines and related compounds. J Clin Pharmacol1986;26:491â€&quot;509.2944917"/>
 <result pre="Anthracyclines and related compounds. J Clin Pharmacol1986;26:491â€&quot;509.2944917 4NitissJL.DNA topoisomerases in" exact="cancer" post="chemotherapy: using enzymes to generate selective DNA damage. Curr"/>
 <result pre="damage. Curr Opin Investig Drugs2002;3:1512â€&quot;6. 5NitissJL.Targeting DNA topoisomerase II in" exact="cancer" post="chemotherapy. Nat Rev Cancer2009;9:338â€&quot;50.19377506 6Cheung-OngK, GiaeverG, NislowC.DNA-damaging agents in"/>
 <result pre="cancer chemotherapy. Nat Rev Cancer2009;9:338â€&quot;50.19377506 6Cheung-OngK, GiaeverG, NislowC.DNA-damaging agents in" exact="cancer" post="chemotherapy: serendipity and chemical biology. Chem Biol2013;20:648â€&quot;59.23706631 7GoodmanLS, WintrobeMM.Nitrogen"/>
 <result pre="hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma," exact="leukemia" post="and certain allied and miscellaneous disorders. J Am Med"/>
 <result pre="strands of duplex DNA. Cancer Res1999;59:4363â€&quot;8.10485484 9DeVitaVT, ChuE.A history of" exact="cancer" post="chemotherapy. Cancer Res2008; 68:8643â€&quot;53.18974103 10EspinosaE, ZamoraP, FeliuJ, BarÃ³nMG.Classification of"/>
 <result pre="Treat Rev2003;29:515â€&quot;23.14585261 11MansooriB, MohammadiA, DavudianS, et al.The different mechanisms of" exact="cancer" post="drug resistance: a brief review. Adv Pharm Bull2017;7:339â€&quot;48.29071215 12BaudinoTA.Targeted"/>
 <result pre="cancer drug resistance: a brief review. Adv Pharm Bull2017;7:339â€&quot;48.29071215 12BaudinoTA.Targeted" exact="cancer" post="therapy: the next generation of cancer treatment. Curr Drug"/>
 <result pre="Adv Pharm Bull2017;7:339â€&quot;48.29071215 12BaudinoTA.Targeted cancer therapy: the next generation of" exact="cancer" post="treatment. Curr Drug Discov Technol2015;12:3â€&quot;20.26033233 13TopculM, CetinI.Endpoint of cancer"/>
 <result pre="of cancer treatment. Curr Drug Discov Technol2015;12:3â€&quot;20.26033233 13TopculM, CetinI.Endpoint of" exact="cancer" post="treatment: targeted therapies. Asian PacJ Cancer Prev2014; 15:4395â€&quot;403. 14MaroneM,"/>
 <result pre="et al.A survey of the anti-apoptotic Bcl2 subfamily expression in" exact="cancer" post="types provides a platform to predict the efficacy of"/>
 <result pre="a platform to predict the efficacy of Bcl2 antagonists in" exact="cancer" post="therapy. Cell Death Dis2010;1:e40â€&quot;e40.21364647 21Modugno)M, BanfiP, GasparriF, et al.Mcl-1"/>
 <result pre="n-substituted isatins as novel class of compounds useful in multidrug-resistant" exact="cancer" post="therapy: in silico and inÂ vitro analysis. Top Curr"/>
 <result pre="of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative" exact="breast cancer" post="MDA-MB-231 cells as apoptosis-inducing agents. J Enzym Inhib Med"/>
 <result pre="some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast" exact="cancer" post="MDA-MB-231 cells as apoptosis-inducing agents. J Enzym Inhib Med"/>
 <result pre="inÂ vitro biological evaluation. Molecules2018;23:1420. 38KasibhatlaS, TsengB.Why target apoptosis in" exact="cancer" post="treatment?Mol Cancer Ther2003;2:573â€&quot;80.12813137 39AhmadR, Vaali-MohammedMA, ElwatidyM, et al.Induction of"/>
</results>
